For patients with previously treated EGFR-mutated NSCLC, a new BLA has been submitted to the FDA seeking the accelerated ...
News Medical on MSN4d
Scientists map cancer mutations in EGFR gene, revealing drug resistance pathsResearchers used base and prime editing to uncover new EGFR gene mutations that affect cancer progression and drug resistance ...
Susan Galbraith, executive vice president, oncology R&D, AstraZeneca, said: “Today’s news reinforces Tagrisso as the backbone therapy in EGFR-mutated non-small cell lung cancer, meeting the critical ...
GlobalData on MSN4h
CHMP recommends AstraZeneca’s Tagrisso for EU approval for NSCLCThe European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca's Tagrisso ...
The CHMP has recommended the Rybrevant-Lazcluze combination as a first-line treatment for adult patients with locally ...
A new study presents a customised treatment strategy using antisense oligonucleotides (ASOs) to target EGFR mutations in ...
New Guidelines Presented at ACR Convergence 2024 Recommend First-Line Therapy with LUPKYNIS ® (voclosporin) as Part of a Triple Immunosuppressive LN Treatment Regimen. ROCKVILLE, ...
Zacks.com on MSN4h
CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLCThe CHMP's opinion is based on late-stage data, which show that treatment with AZN's Tagrisso extends progression-free ...
A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from ...
has recommended approval of Lazcluze in combination with Rybrevant for the first-line treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC). The CHMP ...
Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback